Screener
Hemab Therapeutics Holdings, Inc. COAG Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses | ||||
| Research and development | $20,336 | $12,874 | $39,797 | $26,975 |
| General and administrative | 5,743 | 3,183 | 9,894 | 5,642 |
| Total operating expenses | 26,079 | 16,057 | 49,691 | 32,617 |
| Loss from operations | (26,079) | (16,057) | (49,691) | (32,617) |
| Other income (expense), net | ||||
| Interest income | 2,858 | 335 | 4,077 | 808 |
| Other (expense) income, net | (832) | 3,517 | (1,114) | 4,108 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s total operating expenses?
- Hemab Therapeutics Holdings, Inc. (COAG) reported total operating expenses of $26.08M in Q2 2026.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude